Clinical trial readout dates for United Therapeutics Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 3 Ralinepag PAH; Pulmonary Hypertension · NCT03683186 | December 2026 Enrolling |
| Phase 3 Inhaled Treprostinil Progressive Pulmonary Fibrosis; Interstitial Lung Disease · NCT05943535 | November 2027 Recruiting |
| Phase 2 treprostinil SMI (treprostinil inhalation spray) Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease · NCT07923591 | May 2028 Not Yet Recruiting |
| Phase 1/2 10 GE Xenokidney ESRD (End-Stage Renal Disease); Kidney Transplantation · NCT06878560 | October 2028 Recruiting |
| Phase 1/2 GGTA1 KO Thymokidney ESRD (End-Stage Renal Disease); Kidney Transplantation · NCT07224763 | November 2029 Recruiting |
| Phase 3 Inhaled Treprostinil Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease · NCT04905693 | December 2029 Enrolling |
| Phase 2/3 treprostinil SMI (treprostinil inhalation spray) Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease · NCT07923526 | September 2034 Not Yet Recruiting |
United Therapeutics Corporation reported $3.54B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $259M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |
| 8-K Other Events — often topline trial data | 2026-10-22 |